QPPV.COM KNOWLEDGE ASSESSMENT

Gefurulimab (Klygefa): Dual-Binding C5 Nanobody Development and Pharmacovigilance in Generalised Myasthenia Gravis

Test your understanding of the concepts covered by Gefurulimab (Klygefa): Dual-Binding C5 Nanobody Development and Pharmacovigilance in Generalised Myasthenia Gravis.

Question 1 of 10Pass mark: 80%

Question 1 of 10 How should established experience with eculizumab and other C5 inhibitors inform gefurulimab surveillance?

It should replace product-specific evaluation because all C5 inhibitors have identical pharmacology and use. It should be ignored because gefurulimab has a different molecular format. It can inform biological hypotheses and focused surveillance, while gefurulimab’s own evidence should determine its emerging product-specific profile. It proves that every adverse event reported with another C5 inhibitor is an expected adverse reaction to gefurulimab.

Question 2 of 10 No meningococcal infections were reported among gefurulimab-treated participants during the 26-week controlled PREVAIL period. What is the most appropriate conclusion?

The finding demonstrates that vaccination eliminates meningococcal risk during C5 inhibition. The finding shows that the terminal complement pathway is not important for meningococcal defence in treated patients. No cases were observed in that trial dataset, but its size and duration cannot rule out a rare, mechanistically plausible risk. Meningococcal infection should no longer be monitored because the controlled trial found no cases.

Question 3 of 10 What is the appropriate interpretation of low-titre treatment-emergent anti-drug antibodies reported in the phase I programme?

They establish that all treated patients will lose clinical response over time. They were observed in some subcutaneous recipients without an apparent pharmacokinetic or safety effect in that dataset, but longer-term significance still requires evaluation. They prove that the molecule is not immunogenic in patients with gMG. They demonstrate that complement inhibition was incomplete in every participant with antibodies.

Question 4 of 10 A device study found comparable pharmacokinetic exposure with an autoinjector and a pre-filled syringe under controlled conditions. What does this evidence not establish?

It establishes that no device-related safety reports are necessary after authorisation. It does not eliminate the possibility of use errors, incomplete delivery, device malfunction or non-adherence in routine practice. It proves that injection technique and dose interval cannot affect exposure in real-world use. It demonstrates that all patients will achieve the same clinical response with either device.

Question 5 of 10 Why should aggregate surveillance remain capable of detecting unexpected serious infection patterns beyond meningococcal disease?

Sustained terminal-complement inhibition may alter susceptibility to other infections, and surveillance should be able to identify unexpected patterns without assuming every infection is drug-related. The article establishes that every bacterial infection during treatment is caused by C5 blockade. Only infections confirmed as meningococcal are relevant to pharmacovigilance for a C5 inhibitor. Other infections should be monitored only if they occur at the injection site.

Question 6 of 10 Why does the article consider invasive meningococcal infection a mechanism-based safety concern with gefurulimab?

Terminal complement contributes to defence against Neisseria, and C5 blockade can impair that defence. Albumin binding increases meningococcal growth by providing a nutrient source in serum. Weekly subcutaneous injections cause local immune suppression that is specific to meningococcal bacteria. C5 blockade increases pathogenic AChR antibodies, which directly cause meningococcal infection.

Question 7 of 10 Before the final Klygefa product information is available, how should vaccination and antimicrobial prophylaxis requirements be handled in EU pharmacovigilance materials?

Treat the requirements for every other C5 inhibitor as automatically binding for Klygefa. Omit infection-risk information until a meningococcal case occurs. Avoid presenting other products’ instructions as Klygefa-specific regulatory requirements; use the final authorised Klygefa information when available. Use the phase I study protocol as the final EU risk-minimisation requirement.

Question 8 of 10 How should the reported open-label extension finding of sustained improvement through 52 weeks and no meningococcal infections be used in benefit-risk assessment?

It proves that meningococcal risk has been eliminated after the first 26 weeks of treatment. It replaces the need for routine infection prevention because longer follow-up was reassuring. It adds longer-duration observations but does not disprove a rare, mechanistically plausible infection risk. It establishes that the results apply equally to paediatric patients and all special populations.

Question 9 of 10 Which finding would provide the strongest support for a clinically meaningful immunogenicity concern?

A single positive anti-drug-antibody result without clinical or pharmacological information. A local injection-site reaction after one dose, with no evidence of systemic symptoms. A coherent pattern linking antibody development with altered exposure or complement inhibition and a clinically meaningful change in disease control or hypersensitivity. Detection of low-titre antibodies in a healthy volunteer when no effect on pharmacokinetics or safety was reported.

Question 10 of 10 A patient reports a malfunctioning pre-filled pen and subsequent symptom worsening. What is the best pharmacovigilance handling principle?

Keep the device complaint outside all safety processes because a device issue cannot affect clinical safety. Record only the worsening event and discard information about the presentation and device behaviour. Merge the product-quality investigation and safety case into a single record with no linked processes. Capture device and dose-delivery details, investigate the quality issue through the appropriate process, and ensure associated safety or lack-of-effect information reaches pharmacovigilance.

Gefurulimab (Klygefa): Dual-Binding C5 Nanobody Development and Pharmacovigilance in Generalised Myasthenia Gravis

Cookie Settings